IP Library Granted Patent US 11,752,115
Granted Patent B2
US 11,752,115 · App. 16/014,607 · Granted Sep 12, 2023

PPAR-alpha agonist treatment of neuropsychiatric disorders

Inventors: Graziano Pinna (Chicago, IL); Andrea Locci (Chicago, IL)
Assignee: The Board of Trustees of the University of Illinois
A61K31/16A61P25/22A61P25/24A61K31/045A61K31/192A61K31/216A61K31/402A61K31/403A61K31/421A61K31/422A61K31/505A61K2300/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,752,115
App. No.
16/014,607
Granted
Sep 12, 2023
Kind
B2
Abstract

Described herein are PPARα agonists, including, but not limited to, endocannabinoids that can be used for treatment of a neuropsychiatric disorder and/or symptom thereof. Also described herein are pharmaceutical formulations containing an effective amount of a PPARα agonists, including but not limited to endocannabinoids, where the effective amount is effective for treating a neuropsychiatric disorder and/or symptom thereof. Also described herein are methods of treating a neuropsychiatric disorder and/or a symptom thereof in a subject in need thereof.

Claims (9)

1. A method of treating a post-traumatic stress disorder (PTSD) in a subject in need thereof, the method comprising:

administering an effective amount of an endocannabinoid PPARα agonist to the subject in need thereof, wherein the subject in need thereof has not responded to treatment with one or more selective-serotonin reuptake inhibitors.

2. The method of claim 1 , wherein the endocannabinoid is arachidonoylethanolamine (AEA), oleoyldopamine (OEA), palmitoylethanolamide (PEA), stearoylethanolamide (SEA) or any combination thereof.

3. The method of claim 2 , wherein the endocannabinoid is PEA.

4. The method of claim 3 , wherein the effective amount of PEA can range from about 5 mg/kg to about 20 mg/kg.

5. The method of claim 1 , further comprising the step of detecting a biomarker for PTSD in a sample from the subject in need thereof.

6. The method of claim 5 , wherein the biomarker for PTSD is the amount of endogenous neurosteroids, endocannabinoids and their congeners, or the ratio thereof, in a bodily fluid sample of the subject in need thereof.

7. The method of claim 6 , wherein the neurosteroid comprises allopregnanolone, allopregnanolone sulfate, pregnanolone sulfate, or a combination thereof.

8. The method of claim 6 , wherein the endocannabinoids and their congeners comprises N-Palmitoylethanolamine (PEA), oleoyldopamine (OEA), stearoylethanolamide (SEA), N-arachidonoylethanolamine (AEA), or a combination thereof.

Assignments (2)
CONFIRMATORY LICENSE Recorded Apr 8, 2022
From: OFFICE OF TECHNOLOGV MANAGEMENT OFFICE AT THE UNIVERSITY OF ILLINOIS AT CHICAGO
To: UNITED STATES GOVERNMENT
Reel/Frame 059657/0303 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2018
From: PINNA, GRAZIANO; LOCCI, ANDREA
To: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
Reel/Frame 046277/0973 →
Continuity (2)
Provisional Application 62523015 · Jun 21, 2017
Related Publication 20180369171A1 · Dec 27, 2018